<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="190703">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00610467</url>
  </required_header>
  <id_info>
    <org_study_id>UCI-HS-2006-5162</org_study_id>
    <secondary_id>NIH-CA121568</secondary_id>
    <nct_id>NCT00610467</nct_id>
  </id_info>
  <brief_title>Combined MRI and Optical Imaging to Improved Breast Cancer Diagnosis</brief_title>
  <official_title>Combined MRI and Optical Imaging to Improved Breast Cancer Diagnosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of California, Irvine</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of California, Irvine</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will investigate whether adding the optical imaging to magnetic resonance imaging
      can improve the diagnostic specificity of breast cancer.
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <start_date>October 2006</start_date>
  <primary_completion_date type="Actual">October 2016</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>Open Label</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To prove that combined optical/MRI imaging system can enhance the diagnostic specificity compared to that using MRI alone.</measure>
    <time_frame>at completion of this study</time_frame>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">120</enrollment>
  <condition>Breast Cancer</condition>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>combined optical and MR imaging</intervention_name>
    <description>MRI contrast agent (0.1 mmol/kg) optical contrast agent ICG (0.5 mg/kg)</description>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. A female older than 21 years of age,

          2. Have suspicious imaging findings suggesting a possibility of breast cancer, or
             biopsy-proven breast cancer.

        Exclusion Criteria:

          1. Pregnant,

          2. Unwilling to give informed consent,

          3. Have implanted prosthetic heart valves, pacemaker, neuro-stimulation devices,
             surgical clips (hemostatic clips) or other metallic implants,

          4. Have engaged in occupations or activities which may cause accidental lodging of
             ferromagnetic materials, or have imbedded metal fragments from military activities,

          5. Have received orthodontic work involving ferromagnetic materials,

          6. Claustrophobic,

          7. Have had allergic response to contrast agents (such as iodine or gadolinium)
             previously,

          8. Have known history of severe renal insufficiency, asthma, allergic conditions, sickle
             cell anemia, chronic hemolytic anemia, and gastrointestinal disorders.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>90 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Min-Ying Su, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of California, Irvine</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Center for Functional Onco-Imaging, University of California</name>
      <address>
        <city>Irvine</city>
        <state>California</state>
        <zip>92697</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2016</verification_date>
  <lastchanged_date>December 6, 2016</lastchanged_date>
  <firstreceived_date>January 12, 2008</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of California, Irvine</investigator_affiliation>
    <investigator_full_name>Min-Ying (Lydia) Su</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
